| CPC C07K 14/7051 (2013.01) [A61K 40/11 (2025.01); A61K 40/31 (2025.01); A61K 40/4211 (2025.01); C12N 5/0636 (2013.01); C12N 9/22 (2013.01); C12N 15/63 (2013.01); C12N 15/86 (2013.01); A61K 40/50 (2025.01); A61K 2239/31 (2023.05); A61K 2239/38 (2023.05); A61K 2239/48 (2023.05); C12N 2510/00 (2013.01); C12N 2830/001 (2013.01)] | 15 Claims |
|
1. A method of treating a human subject with CAR therapy in need thereof, comprising administering to the subject a therapeutically effective amount of a human T cell wherein a promoter-less recombinant nucleic acid sequence encoding a CAR is integrated at a site in the genome of the cell, said site being the first exon of the T cell receptor (TCR) alpha chain gene, such that the CAR is expressed under control of the endogenous TCR alpha chain gene promoter, to produce said CAR at the surface of the cell, and wherein integration of the nucleic acid sequence encoding the CAR at said site prevents expression of a functional TCR alpha chain.
|